🇺🇸 FDA
Pipeline program

ALN-4324

ALN-4324-002

Phase 2 small_molecule active

Quick answer

ALN-4324 for Type 2 Diabetes Mellitus (T2DM) is a Phase 2 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ALNYLAM PHARMACEUTICALS, INC.
Indication
Type 2 Diabetes Mellitus (T2DM)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials